Europe Kidney Cancer Therapeutics & Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.70 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Kidney Cancer Therapeutics & Diagnostics Market Analysis
The Europe Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.7% during the forecast period. The major factors driving the growth of the market in the Europe region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.
According to GLOBOCAN 2018, in Germany, there were about 16,416 new kidney cancer cases in 2018 and the mortality was approximately 8,450 cases.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Europe kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.
Europe Kidney Cancer Therapeutics & Diagnostics Market Trends
This section covers the major market trends shaping the Europe Kidney Cancer Therapeutics & Diagnostics Market according to our research experts:
Clear cell RCC Segment is Expected to Hold Major Market Share in the Europe Kidney Cancer Therapeutics & Diagnostics Market
Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles.
According to Kidney Cancer Care Ltd., Kidney cancer is the seventh most common cancer in the UK, which is responsible for around 12,600 new cases every year in the UK which equates to 34 cases every day and up to 30% of all people are diagnosed when in the advanced stage of the disease. Over the last decade kidney cancer incidence has risen by nearly half (47%) and is projected to rise by 26% in the UK between 2014 and 2035.
Furthermore, in 2017, EUSA Pharma and AVEO Oncology announced the first commercial launch of FOTIVDA (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC).
Hence, with high prevalence of the disease and presence of diagnostic procedures and treatment therapies, the segment is expected to witness growth.
Europe Kidney Cancer Therapeutics & Diagnostics Industry Overview
The Europe Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated competitive. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market. Some of the companies which are currently dominating the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, BRISTOL-MYERS SQUIBB COMPANY, Amgen Inc, Novartis AG, Pfizer Inc, and Seattle Genetics.
Europe Kidney Cancer Therapeutics & Diagnostics Market Leaders
-
F. Hoffmann-La Roche Ltd
-
Bayer AG
-
Amgen Inc
-
Abbott Laboratories
-
Bristol-Myers Squibb Company
*Disclaimer: Major Players sorted in no particular order
Europe Kidney Cancer Therapeutics & Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Number of Kidney Cancer Cases
- 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
-
4.3 Market Restraints
- 4.3.1 High Cost Associated with Treatment
- 4.3.2 Preference for Generic Drugs
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
- 5.1.1 Clear cell RCC
- 5.1.2 Papillary RCC
- 5.1.3 Chromophobe RCC
- 5.1.4 Urothelial carcinoma/Transitional cell carcinoma
- 5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
-
5.2 By Component
- 5.2.1 Drugs
- 5.2.1.1 Therapeutic Class
- 5.2.1.1.1 Targeted Therapy
- 5.2.1.1.2 Immunotherapy
- 5.2.1.1.3 Other Therapeutic Class
- 5.2.1.2 By Pharmacologic Class
- 5.2.1.2.1 Angiogenesis Inhibitors
- 5.2.1.2.2 Monoclonal Antibodies
- 5.2.1.2.3 mTOR Inhibitors
- 5.2.1.2.4 Cytokine Immunotherapy (IL-2)
- 5.2.2 Diagnostics
- 5.2.2.1 Biopsy
- 5.2.2.2 Imaging Tests
- 5.2.2.3 Blood Tests
- 5.2.2.4 Other Diagnostics
-
5.3 Geography
- 5.3.1 Europe
- 5.3.1.1 Germany
- 5.3.1.2 United Kingdom
- 5.3.1.3 France
- 5.3.1.4 Italy
- 5.3.1.5 Spain
- 5.3.1.6 Rest of Europe
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc
- 6.1.2 F. Hoffmann-La Roche Ltd
- 6.1.3 Bayer AG
- 6.1.4 Novartis AG
- 6.1.5 Amgen Inc
- 6.1.6 Abbott Laboratories
- 6.1.7 Cerulean Pharma Inc
- 6.1.8 Eisai co Ltd
- 6.1.9 Seattle Genetic
- 6.1.10 BRISTOL-MYERS SQUIBB COMPANY
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Europe Kidney Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The Europe kidney cancer therapeutics & diagnostics market is segmented by cancer type, component and geography.
| By Cancer Type | Clear cell RCC | ||
| Papillary RCC | |||
| Chromophobe RCC | |||
| Urothelial carcinoma/Transitional cell carcinoma | |||
| Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC) | |||
| By Component | Drugs | Therapeutic Class | Targeted Therapy |
| Immunotherapy | |||
| Other Therapeutic Class | |||
| By Component | Drugs | By Pharmacologic Class | Angiogenesis Inhibitors |
| Monoclonal Antibodies | |||
| mTOR Inhibitors | |||
| Cytokine Immunotherapy (IL-2) | |||
| By Component | Diagnostics | Biopsy | |
| Imaging Tests | |||
| Blood Tests | |||
| Other Diagnostics | |||
| Geography | Europe | Germany | |
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe |
Europe Kidney Cancer Therapeutics & Diagnostics Market Research FAQs
What is the current Europe Kidney Cancer Therapeutics & Diagnostics Market size?
The Europe Kidney Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 5.70% during the forecast period (2024-2029)
Who are the key players in Europe Kidney Cancer Therapeutics & Diagnostics Market?
F. Hoffmann-La Roche Ltd, Bayer AG, Amgen Inc, Abbott Laboratories and Bristol-Myers Squibb Company are the major companies operating in the Europe Kidney Cancer Therapeutics & Diagnostics Market.
What years does this Europe Kidney Cancer Therapeutics & Diagnostics Market cover?
The report covers the Europe Kidney Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Kidney Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Kidney Biopsy Industry Report
Statistics for the 2023 Europe Kidney Biopsy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Kidney Biopsy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
